Cancer trials are getting harder to complete, suggesting a role for more powerful RWE, AI solutions

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

OST-HER2 (OST31-164) achieved statistically significant benefit for treated patients in overall survival at the 2.5-year timepoint in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (75% vs. 47%, p = 0.003).